Feed Preview

Influential

Tau Antibody Therapy in Neurodegenerative Diseases

Tau Antibody Therapy in Neurodegenerative Diseases diagram by Kateryna Kon, Shutterstock
Kateryna Kon, Shutterstock

Tau vaccination and administration of anti-tau antibodies can prevent pathology and cognitive impairment in transgenic mouse models of tauopathy, suggesting that therapies which increase anti-tau antibodies might slow the development and/or progression of tauopathies including Alzheimer's disease. Here is the latest research.

Top 20 most recent papers
Nature Reviews. Neurology

Cerebral amyloid angiopathy and Alzheimer disease - one peptide, two pathways

Nature Reviews. NeurologyDecember 13, 2019
Steven M GreenbergSusanne J van Veluw
71
1
2
Frontiers in Neuroscience

The Beta Amyloid Dysfunction (BAD) Hypothesis for Alzheimer's Disease

Frontiers in NeuroscienceDecember 4, 2019
Heinz Hillen
17
1
1
4
1
Lung Cancer : Journal of the International Association for the Study of Lung Cancer

Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry

Lung Cancer : Journal of the International Association for the Study of Lung CancerJanuary 9, 2020
H J M Smitall participants of NVALT Immunotherapy Register (see addendum)
2
1
Drugs of Today

The year's new drugs and biologics 2019

Drugs of TodayFebruary 15, 2020
A I GraulL Sorbera
1
33
1
Annals of Nuclear Medicine

The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease

Annals of Nuclear MedicineFebruary 5, 2020
Maria RicciOrazio Schillaci
1
8
2
36
Neurobiology of Aging

CSF cutoffs for MCI due to AD depend on APOEε4 carrier status

Neurobiology of AgingFebruary 8, 2020
Moira MarizzoniGiovanni B Frisoni
2
1
The Journal of Immunology : Official Journal of the American Association of Immunologists

A 20-Year Journey from Axonal Injury to Neurodegenerative Diseases and the Prospect of Immunotherapy for Combating Alzheimer's Disease

The Journal of Immunology : Official Journal of the American Association of ImmunologistsJanuary 8, 2020
Michal SchwartzHila Ben-Yehuda
8
1
Progress in Molecular Biology and Translational Science

Alzheimer's therapy development: A few points to consider

Progress in Molecular Biology and Translational ScienceNovember 9, 2019
Einar M Sigurdsson
1
7
Acta Neuropathologica Communications

Microglial motility in Alzheimer's disease and after Aβ42 immunotherapy: a human post-mortem study

Acta Neuropathologica CommunicationsNovember 11, 2019
Diana K Franco-BocanegraDelphine Boche
1
1
6
Biomacromolecules

Human Plasma Protein Corona of Aβ Amyloid and Its Impact on IAPP Cross-Seeding

BiomacromoleculesJanuary 8, 2020
Aparna NandakumarPu Chun Ke
2
1
Progress in Neurobiology

Cysteine String Proteins

Progress in NeurobiologyFebruary 12, 2020
Cameron B Gundersen
2

See more papers from this feed

Related Feeds

ALS

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS & FTD: TDP-43

ALS shares with a considerable proportion of FTD cases the same neuropathological substrate, namely, inclusions of abnormally phosphorylated protein tdp-43 (ptdp-43). Here are the latest discoveries pertaining to ptdp-43 and these diseases.

ALS - Pathogenic Mechanisms

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS - Phenotypes

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating phenotypes associated with this genetically heterogeneous disorder.

ALS: Genetics

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here are the latest discoveries pertaining to this disease.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS), also known as motor neuron disease, is associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS therapies here.

ALS: Transposon de-silencing

Transposon silencing is a form of transcriptional gene silencing. These gene silencing mechanisms are impaired in Amyotrophic lateral sclerosis (ALS). Here are the latest discoveries pertaining to transposon silencing and this disease.

Age-related Dementia

Age-related dementia (Alzheimer's disease) results from the destructive impact of the pulse on cerebral vasculature. Evidence is reviewed that the neuropathology of the dementia is caused by the breakdown of small cerebral vessels (silent microbleeds), that the microbleeds result from pulse-induced damage to the cerebral vessels, and that pulse becomes increasingly destructive with age, because of the age-related stiffening of the aorta and great arteries, which causes an increase in the intensity of the pressure pulse. Discover the latest research on age-related dementia here.

© 2020 Meta ULC. All rights reserved
/feed-previews/tau-antibody-therapy-in-neurodegenerative/d55e613b-55f6-4469-92e8-bd3a5ea2c43f